Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Renovaro Inc. (NASDAQ:RENB) by 48.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,332,634 shares of the company’s stock after buying an additional 760,344 shares during the period. Geode Capital Management LLC owned approximately 1.47% of Renovaro worth $1,949,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. State Street Corp raised its stake in Renovaro by 3.8% in the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after acquiring an additional 48,114 shares during the last quarter. Barclays PLC raised its stake in shares of Renovaro by 315.7% in the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after purchasing an additional 52,804 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock worth $45,000 after purchasing an additional 72,230 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Renovaro by 193.3% during the fourth quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock worth $43,000 after purchasing an additional 34,090 shares during the period. Finally, Rhumbline Advisers boosted its position in Renovaro by 122.6% in the fourth quarter. Rhumbline Advisers now owns 112,960 shares of the company’s stock valued at $94,000 after buying an additional 62,204 shares during the last quarter. 71.41% of the stock is owned by hedge funds and other institutional investors.

Renovaro Trading Down 7.0 %

RENB opened at $0.34 on Wednesday. Renovaro Inc. has a 12-month low of $0.32 and a 12-month high of $2.34. The firm has a 50 day moving average of $0.61 and a two-hundred day moving average of $0.77. The firm has a market capitalization of $53.69 million, a PE ratio of -0.36 and a beta of 0.59.

Renovaro (NASDAQ:RENB) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.02) EPS for the quarter.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.